• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

BNT162b2 mRNA vaccine for COVID-19 prevention [Classics Series]

byDeepti Shroff Karhade
July 12, 2022
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. This clinical trial determined the efficacy of the BNT162b2 mRNA vaccine at preventing coronavirus disease 2019 (COVID-19) infection (94.6%) based on comparison to a placebo control group.

2. Rates of serious adverse events did not differ significantly between the BNT162b2 vaccine and control groups.

Original Date of Publication: December 2020

Study Rundown: This clinical efficacy trial compared COVID-19 infection rates of patients receiving the BNT162b2 mRNA vaccine and of those receiving a placebo control. Participants in the streatment group had significantly reduced COVID-19 infection rates when compared to those receiving placebo controls. Vaccine efficacy did not vary based on demographic subgroup analysis. Overall adverse events were higher in the BNT162b2 group, but serious adverse event rates did not differ significantly between groups. The present study has limited generalizability to certain higher risk populations, including children,pregnant individuals and immunocompromised individuals as they were not studied. These groups are commonly excluded from initial safety and efficacy trials to minimize confounding risk factors. In summary, this study demonstrates that the BNT162b2 mRNA vaccine provided a high-degree of COVID-19 protection with limited risk of serious adverse events.

Click to read the study in NEJM

In-Depth [randomized control trial]: This efficacy and safety trial randomized COVID-19 naïve participants to receive two doses of either the BNT162b2 mRNA vaccine (n = 21 720) or a placebo control (n = 21 728). Injections were given intramuscularly 21 days apart in both groups to adults aged 16 years or older. BNT162b2 mRNA vaccine efficacy was measured using rates of COVID-19 infection at least one week following second dose and was found to be 95% (95%CI 90.3-97.6). With only one dose, vaccine efficacy was 52% (95%CI 29.5-68.4). The safety profile of the BNT162b2 vaccine was measured at two-month follow-up. A higher rate of adverse events was reported in the intervention group (27%) as compared to the control group (12%). Serious adverse events did not differ significantly between groups, although safety monitoring will continue for two years after baseline.

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 6

The Scan by 2 Minute Medicine®: the Future of Medicine, Neuralink, the Spotlight on Celine Dion and COVID-19 on Social Media

Moderna mRNA COVID-19 vaccine is safe in children six months to five years of age

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–15.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adverse eventsbnt162b2CoronavirusmRNA vaccine
Previous Post

ARIC study finds obstructive and restrictive spirometry results to be associated with heart failure

Next Post

Inappropriate sleep duration may influence the economic burden of health care

RelatedReports

2MM Podcast

The 2 Minute Medicine Podcast Episode 6

January 13, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: the Future of Medicine, Neuralink, the Spotlight on Celine Dion and COVID-19 on Social Media

December 27, 2022
Infectious Disease

Moderna mRNA COVID-19 vaccine is safe in children six months to five years of age

November 16, 2022
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Infectious Disease

Triple mRNA vaccination and previous COVID-19 exposure provide protection against the omicron variant

November 16, 2022
Next Post

Inappropriate sleep duration may influence the economic burden of health care

siRNA against antithrombin alleviates symptoms of hemophilia [PreClinical]

Routine primary thromboprophylaxis with enoxaparin safe in children with COVID-19 or MIS-C

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

5-day versus 10-day course of remdesivir in patients with severe COVID-19 [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options